GENESIS Tech Transfer Boost invests €50,000 in the funding round of Ownmed Innovation, which closes with a total of €630,000
- Ownmed Innovation's technology provides an alternative to ostomy bags, allowing patients to have greater autonomy and control over waste disposal and improving their quality of life.
- The closure of the Round, led by GENESIS Tech Transfer Boost, will allow the design of a functional prototype, as well as the manufacture of several devices and their clinical validation.
Ownmed is a spin-off born out of the collaboration between the Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIBHGM), the Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz (FIIS-FJD) and the Universidad Carlos III de Madrid (UC3M), founded in 2021 by Ana Ye, Dr. Manuel Desco and Dr. Jesús García-Foncillas and based in Madrid, Spain.
The company specialises in developing advanced solutions to address the challenges associated with ostomy. With a patient-centred approach and backed by a strong scientific basis, Ownmed is dedicated to improving the quality of life of ostomized people through cutting-edge technologies. The company stands out for its commitment to research and development and its ability to translate scientific advances into practical and effective products and services. Its team of professionals, with a solid track record in healthcare and health innovation, is dedicated to applying this cutting-edge technology to enhance clinical outcomes and democratise access to care.
As part of its objective, Ownmed has developed Ostofix, an easy-to-use anti-reflux device that prevents the passage of waste material to the outside. As an alternative to ostomy bags, it allows patients to control the evacuation of their waste with the help of a syringe. This device allows the patient greater autonomy leading to an improvement in their quality of life.
In order to advance in the development of the product, the company has recently successfully closed a €630,000 investment round led by the GENESIS Tech Transfer Boost, investment vehicle managed by GENESIS Biomed, which has invested €50,000, in which other investors in the sector have also participated, together with private investors through the Capital Cell platform.
GENESIS Biomed has also been responsible for carrying out different business activities for Ownmed, including the creation of the business plan, strategic support to the company, as well as accompanying it in the briefing meeting with the AEMPS.
The closure of this Round will allow Ownmed to carry out the design of a functional prototype and the manufacture of several devices to carry out a comparative clinical validation with the available ostomy bags.